Hana Biosciences, Inc. (OTC: HNAB.OB) Is Posting Stable Gains above the $ 0.24 Level
23 Apr 2010

Hana Biosciences, Inc. (OTC: HNAB.OB) has started climbing gradually from the $ 0.20 level since mid-April. Currently the stock is fluctuating within the $0.25 to $ 0.26 range compared to the $ 0.23 to $ 0.24 range from a week ago.

This move may well be considered a favorable reaction to the recent announcement the company made that complete data from its pivotal study of Marqibo(R) in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, have been accepted for presentation at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.

Actually it may be difficult for a quite sophisticated investor to project the time frame and the additional capital outlays that will be required before the company has an approved  product and start recording any income. That’s why it is essential to follow closely the news or  company alerts received from a credible source with proven track record. The company has developed good reporting following its NASDAQ listing period from April 17, 2006 to Septemeber 11, 2009 when the company has moved to the OTCBB.

To the risk loving investors we can recommend a stop loss buy order at this stage with the expectations that the cycle of past week will be repeated. An argument in favor of this strategy is that the market is still anticipating some positive news related to the 46th Annual Meeting of ASCO on June 4-8 in and will be expected to keep or even rise before this date in anticipation of  additional information on progress made by the company.

Hana Biosciences Inc. is a California-based biopharmaceutical company engaged in the development of new and differentiated cancer therapies. The major drugs in the pipeline are Marqibo (vincristine sulphate liposomes injection), Menadione Topical Lotion, Brakiva (topotecan liposomes injection). Alocrest (vinorelbine liposomes injection).

1 Comment
  1. I bought CDIV in Q1 and have done great. Anyone have any thoughts on Q4?
    Any stocks to watch because of BP’s oil mess.

Leave a comment

To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word